Evidence map›Paper›PMID 37530794›Full record

ArticleAnalytical and bioanalytical chemistry2023

Development of novel isobaric tags enables accurate and sensitive multiplexed proteomics using complementary ions.

Miyang Li, Min Ma, Lingjun Li

Open access · greenAbstract read
In one paragraph

Article in Analytical and bioanalytical chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Recent advances and future developments in ultrasensitive omics.Analytical and bioanalytical chemistry · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Miyang Li *Department of Chemistry, University of WI-Madison, Madison, WI, 53706, USA.
Min Ma *School of Pharmacy, University of WI-Madison, 777 Highland Avenue, Madison, WI, 53705, USA.
Lingjun LiDepartment of Chemistry, University of WI-Madison, Madison, WI, 53706, USA. lingjun.li@wisc.edu.ORCID http://orcid.org/0000-0003-0056-3869
University of Wisconsin–Madison · US

Funding

TR&D 2 Metabolic Labels for Ultraplexed Protein Quantification p. 453P41GM108538 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI COON, JOSHUA J · 2016 to 2025
$13.1M
Mass Spectrometric Studies of Neuropeptides in FeedingR01DK071801 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI · 2006 to 2026
$6.7M
Creating a region- specific biomolecular atlas of the brain of Alzheimer’s diseaseR01AG078794 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI, Luigi Puglielli · 2022 to 2026
$3.7M
Di-Leu-enabled multiplexed quantitation for biomarker discovery and validation in Alzheimer's diseaseRF1AG052324 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2018 to 2018
$2.4M
DiLeu-enabled multiplexed quantitation for biomarker discovery and validation in Alzheimer’s diseaseR01AG052324 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI · 2023 to 2026
$2.3M
Acquisition of a High-Field Dual Source FTICR-MS for Pharmaceutical ResearchS10RR029531 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2011 to 2011
$2.1M
Acquisition of a Dual-Source, High-Performance, Ion Mobility, Quadrupole Time-of-Flight Mass Spectrometry System for Biomedical Research at UW-MadisonS10OD028473 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2021 to 2021
$1.3M
Acquisition of a High Resolution High Speed MALDI Mass Spectrometer for Biomedical Research at UW-MadisonS10OD025084 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2018 to 2018
$598k
NCRR NIH HHS S10 RR029531NCRR NIH HHS S10RR029531NIA NIH HHS R01 AG052324NIA NIH HHS R01 AG078794NIA NIH HHS R01AG078794NIA NIH HHS RF1 AG052324NIA NIH HHS RF1AG052324NIDDK NIH HHS R01 DK071801NIDDK NIH HHS R01DK071801NIGMS NIH HHS P41 GM108538NIGMS NIH HHS P41GM108538NIH HHS S10 OD025084NIH HHS S10 OD028473
6 · The paper itself

Abstract

High-throughput quantitative analysis of the cells' proteomes across multiple conditions such as various perturbations and different time points is essential for gaining insights into treatment-induced biological responses or disease pathological states. The advancements in mass spectrometry instrumentation and isobaric labeling methods provided useful tools to help address such demands. However, the current widely adopted isobaric labeling methods such as tandem mass tag (TMT) and isobaric tags for relative and absolute quantitation (iTRAQ) are based on low-mass reporter ions, which are indistinguishable among different peptide analytes, to achieve relative quantification. Therefore, these methods intrinsically suffer from severe ratio distortion when analyzing complex samples due to peptide coelution and cofragmentation. Here, we developed a novel set of isobaric tags named dimethylated leucine complementary ion (DiLeuC) and relied on complementary ions for relative quantification, in which the complementary ions are the remanent peptide segments after fragmentation in the high-mass range. Since those residual peptide fragments are precursor-specific, they retain the relative abundance information in an interference-free manner even in a complex matrix environment. The quantification accuracy of our method was validated in a two-proteome model where the yeast proteome was spiked with a strong background human proteome as interference. In addition, we also applied this strategy to single-cell proteome analysis, demonstrating its potential utility for sensitive high-throughput quantitative proteomics.

Indexed as

ProteomeProteomicsHumansIonsMass SpectrometryPeptidesIonsPeptidesProteomeComplementary ionDiLeuCIsobaric tagsMass spectrometryQuantitative proteomics

Identifiers

PMID37530794
PMCPMC10729713
OpenAlexW4385476712

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.